| dc.description.abstract | Introduction: Lung cancer is one of the leading causes of cancer-related mortality, and systemic therapies such as chemotherapy and targeted therapy (EGFR-TKI) often cause side effects that can affect patients’ quality of life. Understanding the relationship between the type of systemic therapy and its associated side effects is essential for improving the accuracy of clinical management for lung cancer patients. Objective: To analyze the relationship between the type of systemic therapy and the occurrence of side effects in lung cancer patients at H. Adam Malik General Hospital in 2024. Methods: This was a descriptive-analytic study with a cross-sectional design using medical record data. A total of 97 therapy cases were analyzed, consisting of 84 first-line therapies and 13 second-line therapies. The therapy types included platinum-based chemotherapy and EGFR-TKI targeted therapy. Statistical analysis was performed using Fisher’s Exact Test. Results: There was a significant association between the type of systemic therapy and the occurrence of diarrhea (p = 0.016), drug eruption (p = 0.009), skin itching (p = 0.037), and decreased appetite (p = 0.004). Other side effects such as alopecia, nausea and vomiting, fatigue, numbness, dry skin, constipation, joint pain, generalized body pain, and mouth sores showed no significant associations (p > 0.05). Conclusion: The type of systemic therapy is significantly associated with the occurrence of diarrhea, drug eruption, skin itching, and decreased appetite, whereas other observed side effects do not show significant relationships. | en_US |
